Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rubicon Genomics has signed a collaboration agreement with OncoMethylome Sciences for the identification of biomarkers for early detection of cancer.
Subscribe to our email newsletter
Rubicon plans to use its MethylPlex platform to carry out the marker identification analysis. As part of the agreement, Rubicon granted an option to OncoMethylome for licensing markers resulting from the collaboration. This is the second such marker identification agreement between the two companies, and OncoMethylome Sciences has already licensed a set of markers from Rubicon.
Fred Beyerlein, president and CEO of Rubicon Genomics, said: “We believe that detection of methylated DNA biomarkers is the most sensitive and specific method for early detection and characterization of cancer.”